LMT2368 (1-(4-Chlorophenyl)-3-(3-fluoro-5-(trifluoromethyl)phenyl)urea) Negatively Regulates Inflammation by Inhibiting NLRP3 Inflammasome Activation
Pharmaceutics · 23.09.2025 · 17 (10) · 1241
DOI: 10.3390/pharmaceutics17101241 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 23.09.2025. Verfasst von Thai Uy Nguyen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Science, College of Medicine, Korea University, Seoul 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korea Health Industry Development Institute, the Korean government (MSIT).
Abstract (Originalsprache)
Background/Objectives: The dysregulation of NLRP3 inflammasome activation has been established as a key driver of inflammatory disease pathology, which marks NLRP3 as an attractive therapeutic target. However, the clinical development of NLRP3 inhibitors such as MCC950 has been hampered by their associated toxicity profiles, highlighting an unmet clinical need.
Methods
Herein, we present LMT2368, a novel urea-based NLRP3 inhibitor identified through screening of urea-based derivatives from our in-house compound library.
Results
Biolayer interferometry confirmed direct binding of LMT2368 to the NLRP3 NACHT domain with a (KD = 27.4 ± 1.2 μM which was superior to MCC950. Molecular docking studies predicted enhanced binding interactions for LMT2368, consistent with its improved biological activity. In LPS-primed macrophages, LMT2368 dose-dependently suppressed IL-1β secretion (IC50 = 0.8 μM in J774A.1 cells) and caspase-1 activation without affecting NF-κB signaling. Importantly, LMT2368 inhibited ASC oligomerization and pyroptosis while maintaining excellent safety margins (CC50 > 50 μM). In a murine model of LPS-induced acute lung injury, LMT2368 (10 mg/kg) reduced bronchoalveolar lavage fluid immune cell infiltration by 68% (p < 0.001), suppressed pro-inflammatory cytokine release (IL-1β/IL-6/TNF-α), and preserved lung histoarchitecture. Notably, LMT2368 showed selectivity for NLRP3 inhibition without affecting TNF-α/IL-6 production during TLR4 priming in monocytic cell lines.
Conclusions
Together, these findings establish LMT2368 as a promising lead compound for developing safer NLRP3 inhibitors with therapeutic potential for inflammasome-driven diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Science, College of Medicine, Korea University, Seoul 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea.
- Brain Korea 21 Fostering Outstanding Universities for Research, Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University, Seoul 02841, Republic of Korea.
- Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, NY 10065, USA.
- College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea.
- Department of Radiology, College of Medicine Anam Hospital, Korea University, 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea.
ORCID-Profile: Thai Uy Nguyen, Jae Min Cho, Hossam Nada
Förderung
- National Research Foundation of Korea
- Korea Health Industry Development Institute
- the Korean government (MSIT)
- the Ministry of Education of Korea through NRF, and Korea University
- the Ministry of Health and Welfare, Republic of Korea
Zitieren
APA
Nguyen, T. U., Kwon, S. J., Hurh, S., Kale, A., Cho, J. M., Nada, H., Kim, C. S., Induvadana, P., Park, B. J., Lee, K., Choi, Y., & Hwang, J. I. (2025). LMT2368 (1-(4-Chlorophenyl)-3-(3-fluoro-5-(trifluoromethyl)phenyl)urea) Negatively Regulates Inflammation by Inhibiting NLRP3 Inflammasome Activation. Pharmaceutics, 17(10), 1241. https://doi.org/10.3390/pharmaceutics17101241
Vancouver
Nguyen TU, Kwon SJ, Hurh S, Kale A, Cho JM, Nada H, et al. LMT2368 (1-(4-Chlorophenyl)-3-(3-fluoro-5-(trifluoromethyl)phenyl)urea) Negatively Regulates Inflammation by Inhibiting NLRP3 Inflammasome Activation. Pharmaceutics. 2025;17(10):1241. doi:10.3390/pharmaceutics17101241
BibTeX
@article{Nguyen2025,
author = {Nguyen, Thai Uy and Kwon, Su Jeong and Hurh, Sunghoon and Kale, Ashok and Cho, Jae Min and Nada, Hossam and Kim, Chang Seong and Induvadana, Peela and Park, Beom Jin and Lee, Kyeong and Choi, Yongseok and Hwang, Jong-Ik},
title = {LMT2368 (1-(4-Chlorophenyl)-3-(3-fluoro-5-(trifluoromethyl)phenyl)urea) Negatively Regulates Inflammation by Inhibiting NLRP3 Inflammasome Activation},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {10},
pages = {1241},
doi = {10.3390/pharmaceutics17101241}
}
EUVIMED